

Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

arrillig royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Buder 1



Section 1.	Identifying Inform	nation		
1. Given Name (Fi Anna	rst Name)	2. Surname (Last Nam Buder	e)	3. Date 18-March-2020
4. Are you the cor	responding author?	☐ Yes ✓ No	Corresponding Author	or's Name
5. Manuscript Title EGFR mutation t osimertinib		ral in advanced EGFR-m	utated non-small cell lur	ng cancer patients treated with
6. Manuscript Ide TLCR-20-146	ntifying Number (if you kı	now it)		
	ı			
Section 2.	The Work Under C	onsideration for Pu	blication	
any aspect of the s statistical analysis,	ubmitted work (including	g but not limited to grant	s, data monitoring board, st	ent, commercial, private foundation, etc.) for cudy design, manuscript preparation,
Section 3.	Relevant financial	activities outside tl	ne submitted work.	
of compensation	n) with entities as descr	ibed in the instructions	s. Use one line for each er	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.
•	evant conflicts of inter		0	
If yes, please fill o	out the appropriate info	ormation below.		
Name of Entity		Grant? Personal Fees?	Non-Financial Support?	Comments
AstraZeneca				
Section 4.	Intellectual Prope	rty Patents & Cop	yrights	
Do you have any	patents, whether plan	nned, pending or issued	l, broadly relevant to the	work? ☐ Yes ✓ No

Buder 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follow	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Buder report	s personal fees from AstraZeneca, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Buder 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Hochmair 1



Section 1.	Identifying Inform	ation							
1. Given Name (Fii Maximilian			ne (Last Name) ir			3. Date 21-March-2020			
4. Are you the cor	sponding author? Yes No Corresponding Author's Name Martin Filipits								
5. Manuscript Title EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib									
6. Manuscript Ider TLCR-20-146	ntifying Number (if you kr	now it)							
Section 2.	The Work Under Co	onsiderat	tion for Pub	lication					
	ubmitted work (including					ent, commercial, private foundation, etc.) for udy design, manuscript preparation,			
	evant conflicts of intere	est?	∕es ✓ No						
	ı								
Section 3.	Relevant financial	activities	outside the	submitted	work.				
of compensation) with entities as descri	bed in the	instructions.	Use one line fo	or each ei	cial relationships (regardless of amount ntity; add as many lines as you need by e 36 months prior to publication.			
	evant conflicts of intere								
If yes, please fill c	out the appropriate info	ormation b	elow.						
Name of Entity		Grant?	Personal No	on-Financial Support?	Other?	Comments			
AstraZeneca			✓						
Bristol-Myers Squibb			✓						
Boehringer Ingelhein	١		✓			consulting or advisory roles			
Merck Sharp & Dohm	e		✓			consulting or advisory roles			
Pfizer			✓						
Roche			✓			consulting or advisory roles			
Novartis						consulting or advisory roles			

Hochmair 2



Section 4. Intellectual Property Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Section 6. Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Hochmair reports personal fees from AstraZeneca, personal fees from Bristol-Myers Squibb, personal fees from Boehringer Ingelheim, personal fees from Merck Sharp & Dohme, personal fees from Pfizer, personal fees from Roche, personal fees from Novartis, outside the submitted work; .

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Hochmair 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

1. Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Setinek 1



Section 1. Identifying Inform	nation						
1. Given Name (First Name) Ulrike	2. Surname (Last Name) Setinek	3. Date 21-March-2020					
4. Are you the corresponding author?	☐ Yes ✓ No	Corresponding Author's Name Martin Filipits					
5. Manuscript Title EGFR mutation tracking predicts surviva osimertinib	al in advanced EGFR-mutat	red non-small cell lung cancer patients treated with					
6. Manuscript Identifying Number (if you kn TLCR-20-146	now it)						
Section 2. The Work Under Co	onsideration for Public	ation					
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes No							
Section 3. Relevant financial	activities outside the s	ubmitted work.					
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes No							
Section 4. Intellectual Proper	rty Patents & Copyrig	hts					
Do you have any patents, whether plant	ned, pending or issued, bro	oadly relevant to the work? Yes V No					

Setinek 2



Section 5.	
Section 5.	Relationships not covered above
	elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?
Yes, the follo	wing relationships/conditions/circumstances are present (explain below):
✓ No other rela	tionships/conditions/circumstances that present a potential conflict of interest
	anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements rnals may ask authors to disclose further information about reported relationships.
Section 6.	Disclosure Statement
Based on the abo	ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box
Dr. Setinek has r	nothing to disclose.

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Setinek 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"

Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Pirker



Section 1. Identifying Information	ation								
Given Name (First Name) Robert	2. Surnan Pirker	ne (Last Nam	ne)		3. Date 21-March-2020				
4. Are you the corresponding author?									
5. Manuscript Title EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib									
6. Manuscript Identifying Number (if you kno TLCR-20-146	ow it)								
Section 2. The Work Under Co	nsiderat	ion for Pu	ublication						
Did you or your institution at any time received any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interest	but not lim	ited to grant				c.) for			
Place a check in the appropriate boxes in of compensation) with entities as described.	the table	to indicate	whether you ha	ve financ					
clicking the "Add +" box. You should rep	ort relatio				• • • • • • • • • • • • • • • • • • • •				
Are there any relevant conflicts of interest lf yes, please fill out the appropriate info			No						
ii yes, piease iiii out the appropriate inioi		eiow.							
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments				
sstraZeneca		✓							
oehringer Ingelheim		\checkmark			consulting or advisory roles				
Merck Sharp & Dohme		✓			participation in data monitoring committee				
loche		✓							
Gedeon Richter		✓			participation in data monitoring committee				
Genmab					participation in data				

Pirker 2

monitoring committee



Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments		
Regeneron		✓			participation in data monitoring committee		
Section 4. Intellectual Propert					mornioning committee		
Intellectual Propert	y Pate	ents & Cop	pyrights				
Do you have any patents, whether plann	ed, pend	ing or issue	ed, broadly releva	nt to the	work? Yes No		
Section 5. Relationships not c	overed	above					
Are there other relationships or activities potentially influencing, what you wrote i			•	nfluence	d, or that give the appearance of		
Yes, the following relationships/cond	litions/cir	cumstance	es are present (exp	olain belo	ow):		
No other relationships/conditions/cir	cumstan	ces that pre	esent a potential (conflict o	finterest		
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.							
Section 6. Disclosure Statemen							
Disclosure Stateme	nt						
Based on the above disclosures, this form below.	n will auto	omatically (generate a disclos	sure state	ement, which will appear in the box		
Dr. Pirker reports personal fees from Astr & Dohme, personal fees from Roche, per Regeneron, outside the submitted work	sonal fee	•			• •		

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Pirker 3



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

Identifying information.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent

Filipits 1



Identifying Information

Section 1.

ICMJE Form for Disclosure of Potential Conflicts of Interest

1. Given Name (First Name) Martin	2. Surname Filipits	e (Last Nar	me)		3. Date 21-March-2020	
4. Are you the corresponding author?	✓ Yes	No				
5. Manuscript Title EGFR mutation tracking predicts su osimertinib	rvival in advanc	ed EGFR-	mutated non-sma	all cell lun	g cancer patients treated with	
6. Manuscript Identifying Number (if yo TLCR-20-146	ou know it)					
Section 2. The Work Unde	er Considerati	on for P	ublication			
Did you or your institution at any time any aspect of the submitted work (inclustatistical analysis, etc.)? Are there any relevant conflicts of in	ding but not limit	ted to grar				etc.) for
Section 3. Relevant finance	cial activities o	outside	the submitted	work.		
Place a check in the appropriate bo of compensation) with entities as de clicking the "Add +" box. You should Are there any relevant conflicts of in If yes, please fill out the appropriate	escribed in the indicate of th	nstructionships thates	ns. Use one line fo	or each er	ntity; add as many lines as you nee	ed by
Name of Entity	Grant?	Personal Fees?	Non-Financial Support?	Other?	Comments	
AstraZeneca		✓			advisory boards	
Boehringer Ingelheim		✓			advisory boards	
Merck Sharp & Dohme		✓			advisory boards	
Pfizer		✓			advisory boards	
Roche		\checkmark			advisory boards	
Bayer		✓			advisory boards	
Biomedica		✓			advisory boards	
Myriad Genetics Inc.		✓			advisory boards	

Filipits 2



Name of Entity	Grant? Personal Fees?	Non-Financial Support?	Other? Commen	ts	
Eli Lilly			advisory boa	ards	
Section 4. Intellectual Propert	y Patents & Cop	oyrights			
Do you have any patents, whether plann	ed, pending or issue	d, broadly releva	nt to the work?	Yes 🗸 No	
Section 5. Relationships not o	overed above				
Are there other relationships or activities potentially influencing, what you wrote i			nfluenced, or that give	ve the appearance of	
Yes, the following relationships/cond	litions/circumstances	s are present (exp	olain below):		
✓ No other relationships/conditions/cir	cumstances that pre	esent a potential o	conflict of interest		
At the time of manuscript acceptance, jo On occasion, journals may ask authors to					ients.
Section 6. Disclosure Stateme	nt				
Based on the above disclosures, this forn below.	n will automatically g	generate a disclos	sure statement, which	h will appear in the box	
Dr. Filipits reports personal fees from As Sharp & Dohme, personal fees from Pfize Biomedica, personal fees from Myriad G	er, personal fees from	n Roche, personal	l fees from Bayer, per	rsonal fees from	

Evaluation and Feedback

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Filipits 3